1. Home
  2. GVA vs BLTE Comparison

GVA vs BLTE Comparison

Compare GVA & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Granite Construction Incorporated

GVA

Granite Construction Incorporated

HOLD

Current Price

$130.86

Market Cap

5.3B

Sector

Industrials

ML Signal

HOLD

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$137.18

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GVA
BLTE
Founded
1922
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
6.2B
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
GVA
BLTE
Price
$130.86
$137.18
Analyst Decision
Hold
Strong Buy
Analyst Count
3
7
Target Price
$118.33
$198.00
AVG Volume (30 Days)
657.9K
99.6K
Earning Date
04-30-2026
05-08-2026
Dividend Yield
0.42%
N/A
EPS Growth
47.33
N/A
EPS
N/A
N/A
Revenue
$1,762,965,000.00
N/A
Revenue This Year
$13.26
N/A
Revenue Next Year
$6.92
$492.11
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$87.72
$56.68
52 Week High
$145.00
$200.00

Technical Indicators

Market Signals
Indicator
GVA
BLTE
Relative Strength Index (RSI) 45.80 31.51
Support Level $116.73 $103.94
Resistance Level $137.24 $172.02
Average True Range (ATR) 3.75 7.11
MACD -1.69 -1.16
Stochastic Oscillator 22.65 7.06

Price Performance

Historical Comparison
GVA
BLTE

About GVA Granite Construction Incorporated

Granite Construction Inc engages in the construction and development of various infrastructure projects on behalf of public and private clients in the United States. The company focuses on heavy civil infrastructure projects, including roads, highways, transit facilities, airports, bridges, dams, tunnels, and other infrastructure projects. In addition, the company performs site preparation and infrastructure services for residential development, energy development, and other facilities. The majority of revenue is derived from the company's Construction operating segment, and rest from Materials segment.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: